Top Markets
Coin of the day
BioNexus Gene Lab Corporation BioNexus Gene Lab Corporation

BioNexus Gene Lab Corporation

BGLC
株式のランク #18714
BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on... BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming.
株価
$2.49
時価総額
$4.47M
変化(1日)
-4.01%
変化(1年)
678.16%
MY
取引 BioNexus Gene Lab Corporation (BGLC)

カテゴリー

BioNexus Gene Lab Corporation(BGLC)の収益
Sep 2025 時点の収益 TTM: $9.47M
BioNexus Gene Lab Corporation の最新の財務報告によると、現在の収益 (TTM) は $9.47M です。2023 年には $9.77M の収益があり、これは 2022 年の $10.93M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
BioNexus Gene Lab Corporation の収益履歴(2016 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $9.47M -0.48%
2024 $9.51M -2.66%
2023 $9.77M -10.60%
2022 $10.93M -18.21%
2021 $13.36M 17.31%
2020 $11.39M 8,872.03%
2019 $126.96K -40.21%
2018 $212.33K 97.18%
2017 $107.68K 0.00%
2016 0.00 0.00%
同業他社の収益
企業 収益 収益の差
$44.56B 470,644.55%
US
$24.57B 259,466.66%
US
$4.30B 45,369.62%
US
$6.23B 65,758.80%
CN
$7.07B 74,543.38%
US